Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G H Jackson

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Leukemia & Lymphoma|October 24, 2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacyG H Jackson, B Angus, P J Carey, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.
Journal of Medical Genetics|October 26, 2007
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphomaL J Worrillow, A G Smith, K Scott, et al.
Leukemia|December 17, 2015
Genetic factors influencing the risk of multiple myeloma bone diseaseD C Johnson, N Weinhold, J Mitchell, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
Leukemia|January 22, 2010
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemiaJ M Allan, N J Sunter, J R Bailey, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Leukemia|November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia riskG P Sava, H E Speedy, M C Di Bernardo, et al.
Blood Cancer Journal|June 17, 2017
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approachM Went, A Sud, P J Law, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Leukemia & Lymphoma|October 24, 2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacyG H Jackson, B Angus, P J Carey, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.
Journal of Medical Genetics|October 26, 2007
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphomaL J Worrillow, A G Smith, K Scott, et al.
Leukemia|December 17, 2015
Genetic factors influencing the risk of multiple myeloma bone diseaseD C Johnson, N Weinhold, J Mitchell, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
Leukemia|January 22, 2010
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemiaJ M Allan, N J Sunter, J R Bailey, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Leukemia|November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia riskG P Sava, H E Speedy, M C Di Bernardo, et al.
Blood Cancer Journal|June 17, 2017
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approachM Went, A Sud, P J Law, et al.
Pageof 7